Role of Endurance Training in Preventing Pathological Hypertrophy via Large Tumor Suppressor (LATS) Changes

Document Type : Original Article


1 Department of Physical Education, Sharif University of Technology, Tehran, IR Iran.

2 Department of Exercise Physiology, Faculty of Physical Education and Sports Sciences, University of Tehran, Tehran, IR Iran.


Background: One of the negative effects of cardiac sympathetic hyperactivity is pathologic hypertrophy. Recent studies have indicated that large tumor suppressor (LATS) is one of the molecules which play a critical role in cardiomyocyte apoptosis. Considering the preventive role of exercise training, we evaluated the effects of endurance training on LATS gene expression and its upstream pathway in the present study.
Methods: Eighteen male Wistar rats were randomly divided into 2 groups: endurance and control. Endurance training was performed for 8 weeks, 1 hour per day, and 6 days per week on the treadmill at a 15° inclination. Pathologic hypertrophy was induced with the injection of 3 mg/kg-1 of isoproterenol for 7 days; and after 24 hours, the left ventricle was separated and the gene expressions of LATS, MST, and MAP4K were measured. The apoptosis cells of the left ventricle were counted via TUNEL assay. The data were analyzed using the t-test and the Mann–Whitney test.
Results: The gene expressions of LATS and MAP4K in the training group decreased significantly (P ≤ 0.001). In addition, the apoptosis levels of cardiomyocytes in the training group decreased and the left ventricular weight increased significantly. There were no differences in MST gene expression between the groups (P = 0.061).
Conclusions: Our results showed that endurance exercise training diminished LATS suppression by reducing the expression of MAP4K, preventing the propagation of apoptosis induced by hypertrophy in the cardiomyocytes of the Wistar rats.


1. Chowdhury D, Tangutur AD, Khatua TN,
Saxena P, Banerjee SK, Bhadra MP. A
proteomic view of isoproterenol induced cardiac
hypertrophy: prohibitin identified as a potential
biomarker in rats. Journal of translational
medicine. 2013;11(1):130.
2. Silva Jr JA, Santana ET, Manchini MT, Antonio
EL, Bocalini DS, Krieger JE, Tucci PJ, Serra
AJ. Exercise training can prevent cardiac
hypertrophy induced by sympathetic
hyperactivity with modulation of kallikreinkinin pathway and angiogenesis. PLoS One.
2014 10;9(3):e91017.
3. Visser S, Yang X. LATS tumor suppressor: a
new governor of cellular homeostasis. Cell
cycle. 2010 1;9(19):3892-903.
4. Lim S, Mudianto T, Mustaly H, Mauricio IP,
Vittoria MA, Quinton RJ, Howell BW, Cornils
H, Ganem NJ. Identification of STK25 as a
direct activator of LATS signaling. bioRxiv.
2018 1:354233.
5. Lin Z, Pu WT. Harnessing Hippo in the heart:
Hippo/Yap signaling and applications to heart
regeneration and rejuvenation. Stem cell
research. 2014 1;13(3):571-81.
6. Del Re DP, Yang Y, Nakano N, Cho J, Zhai P,
Yamamoto T, Zhang N, Yabuta N, Nojima H,
Pan D, Sadoshima J. Yes-associated protein
isoform 1 (Yap1) promotes cardiomyocyte
survival and growth to protect against
myocardial ischemic injury. Journal of
Biological Chemistry. 2013 8;288(6):3977-88.
7. Meng Z, Moroishi T, Mottier-Pavie V, Plouffe
SW, Hansen CG, Hong AW, Park HW, Mo JS,
Lu W, Lu S, Flores F. MAP4K family kinases
act in parallel to MST1/2 to activate LATS1/2 in
the Hippo pathway. Nature communications.
2015 5;6:8357.
8. Li S, Cho YS, Yue T, Ip YT, Jiang J.
Overlapping functions of the MAP4K family
kinases Hppy and Msn in Hippo signaling. Cell
discovery. 2015 24;1:15038.
9. Ikeda S, Sadoshima J. Regulation of myocardial
cell growth and death by the Hippo pathway.
Circulation Journal. 2016 24;80(7):1511-9.
10. Meng Z, Moroishi T, Guan KL. Mechanisms of
Hippo pathway regulation. Genes &
development. 2016 1;30(1):1-7.
11. Gabriel BM, Hamilton DL, Tremblay AM,
Wackerhage H. The Hippo signal transduction
network for exercise physiologists. Journal of
Applied Physiology. 2016 3;120(10):1105-17.

12. Powers SK, Lennon SL, Quindry J, Mehta JL.
Exercise and cardioprotection. Current opinion
in cardiology. 2002 1;17(5):495-502.
13. Tao L, Bei Y, Zhang H, Xiao J, Li X. Exercise
for the heart: signaling pathways. Oncotarget.
2015 28;6(25):20773.
14. Lin Z, von Gise A, Zhou P, Gu F, Ma Q, Jiang J,
Yau AL, Buck JN, Gouin KA, van Gorp PR,
Zhou B. Cardiac-specific YAP activation
improves cardiac function and survival in an
experimental murine MI model. Circulation
research. 2014 18;115(3):354-63.
15. Kemi OJ, Haram PM, Loennechen JP, Osnes JB,
Skomedal T, Wisløff U, Ellingsen Ø. Moderate
vs. high exercise intensity: differential effects on
aerobic fitness, cardiomyocyte contractility, and
endothelial function. Cardiovascular research.
2005 1;67(1):161-72.
16. Wisløff U, Helgerud J, Kemi OJ, Ellingsen Ø.
Intensity-controlled treadmill running in rats
o 2 max and cardiac hypertrophy. American
Journal of Physiology-Heart and Circulatory
Physiology. 2001 1;280(3):H1301-10.
17. Siddiqui M, Ahmad U, Khan A, Ahmad M,
Badruddeen Khalid M, Akhtar J. Isoprenaline: a
tool for inducing myocardial infarction in
experimental animals. Int J Res Rev Pharm Appl
Sci. 2016; 6:1318-26.
18. Windmueller R, Morrisey EE. Hippo and
cardiac hypertrophy: a complex interaction.
(2015): 832-834.
19. Matsui Y, Nakano N, Shao D, Gao S, Luo W,
Hong C, Zhai P, Holle E, Yu X, Yabuta N, Tao
W. Lats2 is a negative regulator of myocyte size
in the heart. Circulation research. 2008
20. Yang Y, Del Re DP, Nakano N, Sciarretta S,
Zhai P, Park J, Sayed D, Shirakabe A,
Matsushima S, Park Y, Tian B. miR-206
mediates YAP-induced cardiac hypertrophy and
survival. Circulation research. 2015
21. Zheng Y, Wang W, Liu B, Deng H, Uster E, Pan
D. Identification of Happyhour/MAP4K as
alternative Hpo/Mst-like kinases in the Hippo
kinase cascade. Developmental cell. 2015